The stock price of Cellectar Biosciences Inc (NASDAQ: CLRB) has surged by 6.98 when compared to previous closing price of 0.34, but the company has seen a 15.22% gain in its stock price over the last five trading sessions. zacks.com reported 2025-03-18 that Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.
Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?
The 36-month beta value for CLRB is also noteworthy at 0.65. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLRB is 45.31M, and at present, short sellers hold a 4.34% of that float. The average trading volume of CLRB on March 18, 2025 was 2.03M shares.
CLRB’s Market Performance
The stock of Cellectar Biosciences Inc (CLRB) has seen a 15.22% increase in the past week, with a 23.90% rise in the past month, and a 36.48% gain in the past quarter. The volatility ratio for the week is 12.07%, and the volatility levels for the past 30 days are at 9.11% for CLRB. The simple moving average for the past 20 days is 17.01% for CLRB’s stock, with a -77.23% simple moving average for the past 200 days.
Analysts’ Opinion of CLRB
Many brokerage firms have already submitted their reports for CLRB stocks, with Ladenburg Thalmann repeating the rating for CLRB by listing it as a “Buy.” The predicted price for CLRB in the upcoming period, according to Ladenburg Thalmann is $13 based on the research report published on December 05, 2024 of the previous year 2024.
ROTH Capital gave a rating of “Buy” to CLRB, setting the target price at $10 in the report published on January 21st of the previous year.
CLRB Trading at 24.37% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.36% of loss for the given period.
Volatility was left at 9.11%, however, over the last 30 days, the volatility rate increased by 12.07%, as shares surge +12.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.14% upper at present.
During the last 5 trading sessions, CLRB rose by +13.40%, which changed the moving average for the period of 200-days by -87.98% in comparison to the 20-day moving average, which settled at $0.3076. In addition, Cellectar Biosciences Inc saw 20.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLRB starting from Longcor Jarrod, who purchase 30,000 shares at the price of $0.28 back on Jan 10 ’25. After this action, Longcor Jarrod now owns 83,141 shares of Cellectar Biosciences Inc, valued at $8,400 using the latest closing price.
Stock Fundamentals for CLRB
Current profitability levels for the company are sitting at:
- -156.13 for the present operating margin
- 0.32 for the gross margin
The net margin for Cellectar Biosciences Inc stands at -135.05. The total capital return value is set at -3.04. Equity return is now at value -4693.38, with -237.45 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -90.23. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -415.86.
Currently, EBITDA for the company is -51.78 million with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of -51.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.58.
Conclusion
In summary, Cellectar Biosciences Inc (CLRB) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
